SEC Form 4 reporting owner

Brady James Aloysius

Brady James Aloysius has filed 3 Form 4 transactions reported between March 30, 2026 and June 4, 2026, as Director of Xeris Biopharma Holdings, Inc..

Name as filed: Brady James Aloysius

Open-market buys, 24 mo
None
reported
Open-market sales, 24 mo
$60K
1 lines
Companies
1
with Form 4 filings
Latest transaction
Jun 4, 2026
transaction date

Roles and reported holdings

  • XERSXeris Biopharma Holdings, Inc.
    Mar 30, 2026 – Jun 4, 2026

    Director

    Held directly89,166 sh as of Mar 30, 2026 · Form 4

    24 months: $60K sold

Transaction history

All 3 reported transactions, newest first. Every row links to the Form 4 on SEC EDGAR.

DateCompanyTypeSharesValueFiling
Jun 4, 2026XERSDirectorGrant or awardCode A · direct32,996$203K@ $6.15Form 4
Jun 4, 2026XERSDirectorGrant or awardCode A · direct24,193—Form 4
Mar 30, 2026XERSDirectorOpen-market saleCode S · direct10,834$60K@ $5.54Form 4

How this page is built

Every row comes from a Form 4 filed with the SEC, which officers, directors and holders of more than 10% of a company’s stock must file within two business days of a trade. Transactions are grouped by the reporting owner’s name as filed (spacing, capitals and punctuation ignored); two different people filing under an identical name would appear together, and one person filing under two spellings appears on two pages.

Open-market totals count code P purchases and code S sales over the last 24 months. The same trade reported on more than one filing is counted once; when another owner (for example a fund and its general partner) reports the identical trade, they are listed beside it. Holdings are the shares owned after the latest purchase, sale, gift or tax-withholding line, shown separately for direct and indirect ownership; an indirect figure is one holding line, not a total across every trust or entity.

This page describes what was filed with the SEC; it is not investment advice or a recommendation to buy or sell any security.